Navigation Links
YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference
Date:10/1/2010

inistered inhibitor of both the JAK1 and JAK2 kinase enzymes, which have been implicated in a number of immune cell disorders including myeloproliferative disorders and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase I/II trial in myelofibrosis with detailed initial safety and activity data expected at the American Society of Hematology (ASH) meeting in December 2010. Nimotuzumab is a humanized monoclonal antibody targeting EGFR with a potential best-in-class side effect profile. Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide by YM's licensees. CYT997 is a uniquely orally-available agent with dual mechanisms of vascular disruption and cytotoxicity, and is currently in a Phase II trial for glioblastoma multiforme. In addition to YM's three clinical stage products, the Company has a library of more than 4,000 novel compounds identified through internal research conducted at YM BioSciences Australia which are currently being evaluated.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. YM BioSciences licensee Pulmokine awarded NIH funding to develop small molecule drugs for pulmonary hypertension
2. YM BioSciences reports fiscal year end 2010 operational and financial results
3. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
4. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
5. Cardio3 BioSciences Publishes the Science Basis for C-Cure(R) in JACC
6. Signum Biosciences Names Braham Shroot as Chief Executive Officer
7. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
8. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
9. Ambit Biosciences Announces Transition in Company Leadership
10. Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
11. Calithera Biosciences Closes $40 Million in Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... An analysis by Replikins, Ltd. of Pubmed ... CoV virus strains has revealed extensive conservation and ... conservation and sharing of specific Replikin gene structures has ... as it did for the H5N1 influenza vaccine and ... been found to be effective (1,2). ...
(Date:8/26/2014)... of engineers from Singapore has successfully piloted the ... satellite communications. , With the weight of payloads ... a lightweight, low power-consuming, wireless communication system to ... always been a challenge for system designers. , ... of Nanyang Technological University in Singapore launched VELOX-I, ...
(Date:8/26/2014)... Israel , August 26, 2014 ... 3DM, supports NHS hospitals with surgery validation using its Stratasys ... - Performing surgery on 3D printed models prior to ... and provides an effective aid for both patient and surgeon ... SSYS ), a global leader of 3D printing and ...
(Date:8/26/2014)... Aug. 26, 2014  ViveBio, LLC a leading ... stabilization and transportation, announced today that it has ... LLC (LPS) of Knoxville, Tennessee ... the United States . ViveST ... ambient temperature dried biological specimen transport systems.  The ...
Breaking Biology Technology:ZigBee in the Sky 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2
... nanotubessorted by centrifuge for lengthmaterials scientists at the ... made some of the most precise measurements yet ... nanotubes become transparent, conducting sheets. Their recent experiments* ... overly short, but uniform in length nanotubes for ...
... DIEGO, Oct. 15 Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ... third quarter of 2008 on Tuesday, October 21, 2008 ... President and Chief Executive,Officer, will lead the call. On ... the third quarter of 2008., The call will ...
... Reduction in Composite Events When Using Routine ... FFR Guidance in Multi-Vessel Disease, ... announced the launch of the PrimeWire(TM) Pressure,Guidewire, and the s5-FFR ... consoles in the U.S. The PrimeWire is Volcano,s newest pressure,guidewire, ...
Cached Biology Technology:Paperwork: Buckypapers clarify electrical, optical behavior of nanotubes 2Amylin Pharmaceuticals to Webcast Third Quarter Results 2Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 2Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 3Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 4Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 5
(Date:8/26/2014)... a protective tent over a colony of harmful ... especially difficult. Microorganisms protected in a biofilm pose ... resistance and recalcitrance to treatment, and biofilm-protected bacteria ... infections in humans and are 50 to 1,000 ... infections. , "In essence, we may have stumbled ...
(Date:8/26/2014)... increasing pressure from policymakers, consumers, and suppliers has ... beyond reducing the pollutants they emit from their ... companies must also assess environmental performance at every ... primary materials to the use and recycling of ... to the discipline known as life cycle engineering, ...
(Date:8/26/2014)... New Jersey Institute of Technology (NJIT), is helping to ... the pace for daily life. , Evolution has harmonized ... fundamental rhythms of life that include the cycle of ... change. The brain,s circadian clock controls hormone production related ... by experiences such as jet lag or night-shift work, ...
Breaking Biology News(10 mins):Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3Yale journal explores advances in sustainable manufacturing 2Researching fundamental rhythms of life 2Researching fundamental rhythms of life 3
... in response to vibrations within the inner ear, could form ... way to do this could be with gene therapy that ... Emory University School of Medicine have shown that introducing a ... induce the formation of extra sensory hair cells. Their ...
... in infant rats demonstrates that the anti-epilepsy drug phenobarbital ... using the first-line drug to treat epilepsy in human ... posted online May 11, researchers at Georgetown University Medical ... to rat pups about a week old changed the ...
... findings show that embryonic stem cells unable to fully ... task: differentiation into specific cell types that give rise ... the body. Researchers from the Georgia Institute of ... required for proper embryonic stem cell differentiation to occur. ...
Cached Biology News:Gene therapy for hearing loss: Potential and limitations 2Study raises questions about use of anti-epilepsy drugs in newborns 2Study raises questions about use of anti-epilepsy drugs in newborns 3Successful stem cell differentiation requires DNA compaction, study finds 2Successful stem cell differentiation requires DNA compaction, study finds 3Successful stem cell differentiation requires DNA compaction, study finds 4
Human VASA Biotinylated Affinity Purified PAb...
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
An instrument that delivers an accurate and uniform amount of light energy to cells to photoactivate csiRNA products....
Biology Products: